Floxacillin

Summary

Floxacillin (CHEMBL222645) is a phase-3 clinical-stage small-molecule antibacterial drug (ATC J01CF05); indicated across 7 conditions including bacterial infectious disease and skin disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01CF05
• Indications: 7 conditions
• Clinical trials: 14
• Chemistry: 453.9 Da · C19H17ClFN3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL222645
Name	Floxacillin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	21319
ChEBI	CHEBI:5098
ATC	J01CF05
Molecular formula	C19H17ClFN3O5S
Molecular weight	453.9
InChIKey	UIOFUWFRIANQPC-JKIFEVAISA-N

SMILES: CC1=C(C(=NO1)C2=C(C=CC=C2Cl)F)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O

IUPAC name: (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin compound having a 6β-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Abboflox, BRL 2039, BRL-2039, Culpen, Floxacillin, Floxacillin sodium, Floxacillin sodium anhydrous, Floxapen, Fluclomix-250, Fluclomix-500, Flucloxacilina, Flucloxacillin

Parent form; salt/anhydrous children: CHEMBL283053, CHEMBL3187256

Patent coverage: 5,029 distinct patent families (18,757 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Bile salt export pump.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
skin disorder	3	MONDO:0005093	EFO:0000701
staphylococcus aureus infection	3	MONDO:0005545	EFO:0005681
cellulitis	3	MONDO:0005230	EFO:0003035
osteomyelitis	2	MONDO:0005246	EFO:0003102
chronic kidney disease	1	MONDO:0005300	EFO:0003884

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE4	4
Not specified	4
PHASE1	3
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01876628	PHASE4	COMPLETED	Adjunctive Clindamycin for Cellulitis: C4C Trial.
NCT02032654	PHASE4	TERMINATED	Duration of ANtibiotic Therapy for CEllulitis
NCT02922686	PHASE4	UNKNOWN	Penicillin for the Emergency Department Outpatient Treatment of CELLulitis
NCT03632642	PHASE4	WITHDRAWN	Penicillin Against Flucloxacillin Treatment Evaluation
NCT01792804	PHASE3	COMPLETED	Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT02814916	PHASE3	COMPLETED	Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
NCT00428844	PHASE2	COMPLETED	Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci
NCT00358371	PHASE1	COMPLETED	Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)
NCT00433342	PHASE1	TERMINATED	The Effect of Antimicrobial Therapy on the Serum Level of P-cresol in Peritoneal Dialysis Patients
NCT04840641	PHASE1	COMPLETED	Flucloxacillin as an Inducer of CYP-enzymes
NCT00405158	Not specified	COMPLETED	Study of Acupuncture and Care Interventions for the Treatment of Breast Inflammation During Breastfeeding
NCT02334124	Not specified	COMPLETED	Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital
NCT02993575	Not specified	COMPLETED	Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients
NCT06454643	Not specified	COMPLETED	Gentamicin in Cardiac Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of DPWG Guideline for flucloxacillin and HLA-B	DPWG	HLA-B		yes

PharmGKB also curates 2 clinical and 17 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).